

FT-EZ280

## Mouse IgG1 Isotype Control Low Endotoxin

The specificity of staining by monoclonal antibodies to target antigens should be verified by establishing the amount of non-specific antibody binding. Especially at higher concentration (more than 15  $\mu$ g/ml) the antibody staining usually has consignable background. To this end a non-reactive immunoglobulin of the same isotype is included as a negative control for each specific monoclonal antibody used in a particular immunoassay. The monoclonal antibody MOPC-21, generated against an undefined antigen, does not react specifically with rat and human samples, and hence all the background that could be observed when working with this antibody would be a result of general nonspecific interactions between an mouse IgG1 molecule and the respective sample under the particular conditions. This shall help the customer to set up the experimental conditions so that the nonspecific binding of any antibody is abolished.

Cat# :	EZG280	100 µg
Clone:	MOPC-21	
Isotype:	Mouse IgG1	
Specificity:	This mouse IgG1 kappa monoclonal antibody (clone MOPC-21) has unknown specificity and was chosen as an isotype control after screening on variety of resting, activated, live and fixed rat and human tissues.	
Negative Species:	Human, Rat	
Application:	Flow Cytometry Immunoprecipitation Western Blotting Immunohistochemistry (paraffin sections) Immunohistochemistry (frozen sections) Control Experiments The antibody is suitable for control experiments when performing cell surface staining as well as intracellular staining.	
Purity:	>95% (by SDS-PAGE).	
Purification:	Purified from cell culture supernatant by protein-G affinity chromatography.	
Concentration:	1 mg/ml	
Storage Buffer:	Azide free phosphate buffered saline (PBS), approx. pH 7.4; 0.2 µm filter sterilized. Endotoxin level is less than 0.01 EU/µg of the protein, as determined by the LAL test	
Storage / Stability:	Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.	
References:	*Carlsten M	, Björkström NK, Norell H, Bryceson Y, van Hall T, Baumann BC, Hanson M,

LIFE SCIENCES

terchir



FT-EZG280

Schedvins K, Kiessling R, Ljunggren HG, Malmberg KJ: DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res. 2007 Feb 1;67(3):1317-25.

\*Smed-Sörensen A, Moll M, Cheng TY, Loré K, Norlin AC, Perbeck L, Moody DB, Spetz AL, Sandberg JK: IgG regulates the CD1 expression profile and lipid antigen-presenting function in human dendritic cells via FcgammaRIIa. Blood. 2008 May 15;111(10):5037-46.

\*Yates J, Rovis F, Mitchell P, Afzali B, Tsang JY, Garin M, Lechler RI, Lombardi G, Garden OA: The maintenance of human CD4+ CD25+ regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro. Int Immunol. 2007 Jun;19(6):785-99.

\*Wiendl H, Mitsdoerffer M, Schneider D, Melms A, Lochmuller H, Hohlfeld R, Weller M: Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. Brain. 2003 May;126(Pt 5):1026-35.

\*Bryceson YT, March ME, Barber DF, Ljunggren HG, Long EO: Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J Exp Med. 2005 Oct 3;202(7):1001-12.

\*Rebetz J, Tian D, Persson A, Widegren B, Salford LG, Englund E, Gisselsson D, Fan X: Glial progenitor-like phenotype in low-grade glioma and enhanced CD133-expression and neuronal lineage differentiation potential in high-grade glioma. PLoS One. 2008 Apr 9;3(4):e1936.

For in vitro research use only